Product Description
CLB-3000 is a therapeutic vaccine designed to drive functional cure of hepatitis B. (Sourced from: https://clearbtherapeutics.com/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ClearB Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis B, Chronic|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12623000841673 | P1 |
Completed |
Intestinal Diseases|Hepatitis B, Chronic |
2025-02-03 |
2025-07-26 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/29/2024 |
News Article |
ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024 |
|
10/12/2023 |
News Article |
ClearB Therapeutics Announces First Patient Dosed in a Phase 1b |
|
06/20/2023 |
News Article |
ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023 |
|
10/24/2022 |
News Article |
ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 |